Key Takeaways
- Researchers suggest antivirals targeting Epstein-Barr virus could be the most effective MS treatment.
- Study indicates CD4 T-cells in people with MS target active viral proteins more frequently than those without the condition.
- T-cell responses to EBV decrease significantly after B-cell reduction treatments in MS patients.
A groundbreaking study suggests that antiviral drugs targeting the Epstein-Barr virus (EBV) could be the most effective treatment for multiple sclerosis (MS). The research, led by scientists at Harvard Medical School and the Harvard T.H. Chan School of Public Health, has identified a potential new approach to managing this debilitating condition.
Multiple sclerosis is characterized by an immune attack on myelin, a protective sheath that wraps around nerve fibers. This damage can lead to a wide range of symptoms including muscle weakness, fatigue, and cognitive impairment. Current treatments primarily focus on suppressing the immune system, but researchers are now exploring whether targeting EBV could offer more specific benefits.
The study found that CD4 T-cells in people with MS predominantly target viral proteins produced during active replication of EBV, rather than those associated with its dormant state. This finding suggests a unique immune response to EBV in individuals who develop MS. In contrast, healthy individuals have fewer such cells targeting the virus.
To further investigate this link, the team examined T-cell responses in 60 people with MS before and after they began treatments that reduce their number of B-cells. These treatments are known to decrease the overall immune response but also specifically target EBV. The results showed a significant reduction in T-cell responses to EBV almost to the levels seen in individuals without MS.
Kjetil Bjornevik, a team member from Harvard T.H. Chan School of Public Health, stated: 'I think most MS researchers now would agree that EBV plays a major role in the development of the disease.' This consensus among experts highlights the growing importance of understanding the relationship between EBV and MS.
Natalia Drosu, another team member from Massachusetts General Hospital, added: 'Our question for this study was: in people with MS, what parts of EBV does the immune system respond to? And do those responses look different from people who don’t have MS?' Her research provides a clearer picture of how the immune response to EBV may differ between individuals with and without MS.
Michael Levy, also from Harvard Medical School, emphasized: 'There aren’t good Epstein-Barr virus drugs currently available, but they can be developed. That might be the most useful specific therapy for MS in the future.' This statement underscores the potential for new treatments to emerge as a result of this research.
While these findings are promising, further studies will be necessary to confirm the role of EBV in MS and to develop effective antiviral therapies. The researchers hope that their work will lead to more targeted treatment options for people living with multiple sclerosis.
I think most MS researchers now would agree that EBV plays a major role in the development of the disease.
Kjetil Bjornevik, Harvard T.H. Chan School of Public Health
There aren’t good Epstein-Barr virus drugs currently available, but they can be developed. That might be the most useful specific therapy for MS in the future.
Michael Levy, Harvard Medical School
